Nektar Therapeutics stock is up 12% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.33% of the previous 29 December’s closed higher than November. 0% of analysts rate it a buy.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus